Using Spectral CT Scans to Improve Detection of Metastatic Colorectal Cancer
Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study
Centre Hospitalier Universitaire de Saint Etienne · NCT06024837
This study is testing whether a new type of CT scan can help doctors find liver cancer spread in patients with colorectal cancer to improve their treatment and surgery plans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Saint-Etienne) |
| Trial ID | NCT06024837 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of spectral CT scans in detecting liver metastases and peritoneal carcinosis in patients with colorectal cancer. It aims to improve tumor detection by utilizing dual-energy scanning technology, which allows for better imaging with reduced iodine dose and radiation exposure. The study focuses on patients who are candidates for curative surgical resection, assessing how spectral CT can enhance surgical planning and outcomes. By comparing spectral CT results with conventional imaging, the study seeks to establish the clinical benefits of this advanced imaging technique in oncology.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with colorectal cancer who have liver metastases and/or peritoneal carcinosis and are planned for curative surgical resection.
Not a fit: Patients with non-metastatic colorectal cancer or those with extra-hepatic and extra-peritoneal metastases will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved detection rates of metastatic lesions, potentially enhancing surgical outcomes and survival rates for patients with colorectal cancer.
How similar studies have performed: While spectral CT has shown promise in other imaging applications, its specific use in oncology for colorectal cancer detection is relatively novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients followed for colorectal cancer with synchronous or metachronous liver metastases and/or peritoneal carcinosis * Patients with a curative surgical resection plan Exclusion Criteria: * Patients with non-metastatic colorectal cancer * Patients treated with chemotherapy without surgical plans * Patients with colorectal cancer with extra-hepatic and extra-peritoneal metastases alone (e.g. lung, bone)
Where this trial is running
Saint-Etienne
- CHU Saint-Etienne — Saint-Etienne, France (RECRUITING)
Study contacts
- Principal investigator: Rémi GRANGE, MD — Centre Hospitalier Universitaire de Saint Etienne
- Study coordinator: Rémi GRANGE, MD
- Email: remi.grange@chu-st-etienne.fr
- Phone: (0)477828963
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Colo-rectal Cancer, Colo-rectal cancer, spectral CT scan, liver metastases, peritoneal carcinosis